Universiteit van die Oranje-Vrystaat - SAMJ Archive Browser

that ipsapirone HCl may be administered to
who are receiving insulin. This study
set out to examine the effect, if any, of
ipsapirone on the blood glucose profiles of
insulin patients.
m open study was conducted in fifteen diabetic
persons (8 males and 7 females) who continued on
their normal insulin dose throughout the study.
~lood samples were drawn to determine glucose
levels on Day 1 (baseline) of the study, on Day 2
after a single dose of ipsapirone HC1 5mg and on
Day 7 after multiple doses of ipsapirone HC1 5mg
t.i.d. Ipsapirone concentrations were also
determined from the blood samples drawn on Days 2
and 7.
The geometric means of the plasma glucbse AUC(O-
5h) on DBys 1, 2 and 7 were 56.9, 48.1 and 44.7
mmol.h/ml respectively. The corresponding mean
oh glucose levels were 10.0, 7.21 and 6.69
mmol/l. After correcting for differences in Oh
glucose levels, it was shown that a single dose
of ipsaplrone HC1 does not influence glucose
levels in patients stabilised on insulin. It was
necessary to correlate AUC(0-8h) of ipsapirone on
Day 7 with the difference in glucose AUC(0-5h)
between Days 1 and 7 to show that this also holds
after multiple dosing of ipsapirone HC1.
It is concluded that the addition of ipsapirone
HC1 to existing insulin regimens does not affect
blood glucose control; adjustment of insulin
dosage should not be required.
ConcLsion: Excessive phagocytosis of carbon parCdes - to such an
erdentlhatthemaprityofmacrophagescontainmoreIhanaOcarbon
parfidea;inhibitsingestionof~~arganiwrslhis
ewklpiayanrajorrdeinthepalhophysidogyof-amongst
Blacks
SAMJ VOL 80 7DEC 1991 621
A NEW MOLECULAR GENETICS LABORATORY IN
BLOEM FONTEBN.
W.M. ~oslw*, W WoWdt
Dept. of Haematology, Dept. of Neurology,
U.O.F.S., Bloemfontein.
Extraordinary props in the understanding of the
structure and funmon of human genes has been made in
the past 25 years. Techniques have been developed for
the manipulation and study of genes in both normal and
abnormal states. Many of these achievements have been
extremely importaqt to medicine, and have led to the
osis of base defects at the DNA hel and
un erstanding of the bimical mechanisms af several
diseases.
The use of DNA probe testing for several single gene
disorders has been increasing since this development
was first reported in 1978. Because of the importance of
early diagnosis in MEN 24 prenatal diagnosis and ability
to distinguish carrier females from non-carriers In
Hemophilia A, we decided to undertake a p~lot study with
the purpose of establishing a routine service.
In this poster we describe the disorders for which we are
trying to establish a routine service. Although our
research is still in an experimental stage, we report a few
interesting findings, and hope to provide a routine service
in the near future. . % J - ~ ~
, , -
ME CLINICAL PHARMACOLOGY OF ANTICOAGULANT rDNA
- HIRUDIN.
B.H. Meyer, F.O. Muller, H.G. Luus, H.-J.
Rothig* and H. Grotsch*.
Dept. of Pharmacology, University of the Orange
Free State, Bloemfontein, South Africa.
*Hoechst AG, Frankfurt, Federal Republic of
Germany.
Recombinant hirudin in single and multiple in-
travenous and subcutaneous doses ranging between
0.01 and 0.5 mg/kg, was given to 89 healthy -
males to investigate its tolerability, phar-
macokinetics and -dynamics.
The compound was tolerated we1 l . The el imination
half-life of hirudin in plasma was about 1 hour;
total clearance about 220 ml/min; renal
clearance about 100 ml/min. For our dose range
it obeys first-order pharmacokinetics.
Both activated partial thromboplastin time
(aPTT) and 'thrombin time (TT) were dosedepen-
dently increased by hirudin. For our dose range
the correlation coefficient (r) between increase
above base1 ine of aPl7 (y) and hirudin plasma
concentrations (X) was 0.92 and a l inear
relationship between the two variables: y =
10.43 + 0.06~ was a satisfactory approximation.
Hirudin elicited large increases in TT.
Conclusion: Hirudfn is tolerated well and yields
predictable anticoagulant effects.